Formerly a division of Sanofi-Synthélabo, Ceva has been a leading independent animal health company since 1999, developing, manufacturing and marketing pharmaceutical products (54% of sales), vaccines and biological products (46% of sales). These products are intended for both farm animals (69% of sales) and companion animals (31% of sales).

​

Ceva, headquartered in Libourne (France), boasts over 7,000 employees across 47 countries, with distribution channels in more than 110 countries. The Company has also built strong in-house manufacturing capacity through 33 production sites and significant R&D capabilities with 15 research centers.

​

NiXEN, had already been a Ceva investor between 2007 and 2014 and ; has chosen to participate in this transaction as a co-investor alongside ARCHIMED, in order to support the management team in the next stages of the company's development, notably international growth and expansion.

​
“We will continue to strengthen our position in vaccines, both for companion animals and for animal production. We have also just launched a range of mild shampoos for dogs and cats [...] We can still strengthen our position in certain countries, such as Japan. In other countries, we only distribute part of our product range. Development opportunities remain significant.”

​

Marc Prikazsky, CEO of Ceva
(Source : CFNews)